(VIANEWS) – CTT CORREIOS PORT (CTT.LS), NAVAMEDIC (NAVA.OL), SALMAR (SALM.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. CTT CORREIOS PORT (CTT.LS)
327.5% sales growth and 22.58% return on equity
CTT – Correios De Portugal, S.A., together with its subsidiaries, provides postal and financial services worldwide. It operates through Mail, Express & Parcels, Financial Services & Retail, and Bank segments. The company offers courier and urgent mail transport services; postal financial services; and banking services. It also engages in the business of payments related to collection of invoices and fines. In addition, the company enables the payment of various services and utilities through a network of approximately 5,000 agents covering business outlets as stationery stores, tobacco shops, kiosks, and supermarkets. It operates a retail network of 566 post offices; 1,808 postal agencies; 223 postal delivery offices; 4,576 postal delivery routes; and a fleet of 3,925 vehicles. The company was formerly known as Correio Publico. CTT – Correios De Portugal, S.A. was founded in 1520 and is headquartered in Lisbon, Portugal.
Earnings Per Share
As for profitability, CTT CORREIOS PORT has a trailing twelve months EPS of €0.11.
PE Ratio
CTT CORREIOS PORT has a trailing twelve months price to earnings ratio of 33.91. Meaning, the purchaser of the share is investing €33.91 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.58%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on May 18, 2022, the estimated forward annual dividend rate is 0.12 and the estimated forward annual dividend yield is 3.41%.
2. NAVAMEDIC (NAVA.OL)
72.2% sales growth and 16.31% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, women's health, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr0.47.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 81.49. Meaning, the purchaser of the share is investing kr81.49 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.31%.
Moving Average
NAVAMEDIC’s value is way higher than its 50-day moving average of kr34.10 and way above its 200-day moving average of kr32.14.
Volume
Today’s last reported volume for NAVAMEDIC is 21063 which is 8.3% below its average volume of 22970.
Revenue Growth
Year-on-year quarterly revenue growth grew by 28.6%, now sitting on 382.14M for the twelve trailing months.
3. SALMAR (SALM.OL)
45.8% sales growth and 18.21% return on equity
SalMar ASA, an aquaculture company, produces and sells farmed salmon in Asia, the United States, Canada, Norway, rest of Europe, and internationally. It is involved in the broodfish, lumpfish, and smolt production activities; and marine-phase farming, harvesting, packaging, processing, and selling farmed salmon. The company sells its products to importers/exporters, processing companies, and retail chains through in-house sales force and/or through partners. SalMar ASA was founded in 1991 and is headquartered in Kverva, Norway.
Earnings Per Share
As for profitability, SALMAR has a trailing twelve months EPS of kr17.49.
PE Ratio
SALMAR has a trailing twelve months price to earnings ratio of 23.87. Meaning, the purchaser of the share is investing kr23.87 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.21%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 9, 2022, the estimated forward annual dividend rate is 20 and the estimated forward annual dividend yield is 4.63%.
Moving Average
SALMAR’s value is under its 50-day moving average of kr420.83 and way under its 200-day moving average of kr504.50.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SALMAR’s EBITDA is 43.28.
Sales Growth
SALMAR’s sales growth is 11.5% for the ongoing quarter and 45.8% for the next.
4. TER BEKE (TERB.BR)
6.8% sales growth and 3.73% return on equity
Ter Beke NV, together with its subsidiaries, develops, produces, and sells a range of processed meat products and ready meals to discount and retail clients in Europe. It operates through two segments, Processed Meats and Ready Meals. The Processed Meats segment develops, produces, and sells a range of processed meats, including salami, cooked ham, poultry, other cooked meats, pâtés, preserved meats, tongue, and liver products under the Pluma, Daniël Coopman, Zonnenberg, Kraak-Vers, and FairBeleg brand names, as well as other private labels. The Ready Meals segment develops, produces, and sells freshly prepared ready meals including lasagne, pizza, pasta dishes, and sauces under the Come a casa, Vamos, and Stefano Toselli brand names, as well as private labels. Ter Beke NV was founded in 1948 and is based in Gent, Belgium. Ter Beke NV is a subsidiary of Stak Coovan.
Earnings Per Share
As for profitability, TER BEKE has a trailing twelve months EPS of €-1.36.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.73%.
Volume
Today’s last reported volume for TER BEKE is 836 which is 82.53% above its average volume of 458.
